| Metric | Q3 FY26 | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Other income | 0.9 | 0.8 | 1.1 |
| Total income | 25.5 | 34.3 | 29.0 |
| Net profit | 1.3 | 1.2 | 1.4 |
| Operating margin | 7.1% | 5.0% | 6.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -7.10% |
|---|---|
| Net profit, quarter on quarter | +8.30% |
BSE results filing, NSE: VAISHALI. Figures extracted from the filing.
Vaishali Pharma Ltd: key numbers
- Share price
- ₹8.39
- Market cap
- ₹113.3 Cr
- Revenue (annual)
- ₹108.8 Cr
- Net profit (annual)
- ₹4.16 Cr
- P/E (TTM)
- 25.6×Sector 49.8×
- Promoter holding
- 30.54%-1.07% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vaishali Pharma Ltd
All →Vaishali Pharma Annual General Meeting
Vaishali Pharma Limited concluded its 19th Annual General Meeting on September 24, 2026, via video conferencing, transacting routine ordinary business matters.
Vaishali Pharma Capital Structure Change
Vaishali Pharma Ltd received listing approval from NSE for 45,37,865 equity shares issued on a preferential basis, subject to depository confirmation.
Vaishali Pharma Annual General Meeting
Vaishali Pharma Limited will hold its 19th Annual General Meeting on September 24, 2026, through video conferencing to transact ordinary business.
Vaishali Pharma Management Change
Vaishali Pharma Limited announced the resignation of Mr. Bhaveshkumar Popatlal Upadhyay from the position of Non-Executive Independent Director, effective August 14, 2026.
Vaishali Pharma Q1 FY27 Results: Net Profit ₹1.5 Cr, Up 15.4% YoY
Vaishali Pharma Ltd reported revenue from operations of ₹22.9 Cr (-3.4% YoY) and net profit of ₹1.5 Cr (+15.4% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1.5 Cr · +15.4% YoY
Vaishali Pharma Board Meeting Date
Vaishali Pharma Limited scheduled a board meeting for August 14, 2026, to approve the standalone and consolidated unaudited financial results for the quarter ended June 2026.